Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03099161 |
| Title | Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062) |
| Recruitment | Terminated |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Merck Sharp & Dohme Corp. |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | ISR | CAN |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| START Midwest ( Site 0001) | Grand Rapids | Michigan | 49546 | United States | Details | |
| Princess Margaret Hospital ( Site 0010) | Toronto | Ontario | H9H 4M7 | Canada | Details | |
| Jewish General Hospital ( Site 0011) | Montreal | Quebec | H9H 4M7 | Canada | Details | |
| Rambam Health Care Campus ( Site 0020) | Haifa | Israel | Details | |||
| Tel Aviv Sourasky Medical Center ( Site 0021) | Tel Aviv | Israel | Details |